Tresiba Microdosing Protocols: What the Evidence Actually Shows

What "Microdosing" Means for Basal Insulin

The term microdosing has no regulatory or pharmacopoeial definition when applied to basal insulin. In GLP-1 and peptide contexts it typically means administering a fraction of the standard therapeutic dose to reduce side effects while preserving a partial pharmacological effect. Applied to insulin degludec, the phrase is used clinically in three distinct scenarios.

Three Practical Contexts for Sub-Standard Dosing

First, dose-ranging below 0.1 U/kg/day in highly insulin-sensitive patients, particularly lean adults with type 1 diabetes or latent autoimmune diabetes in adults (LADA). Second, sub-unit dosing precision in children, where a 1-unit minimum delivery still represents a large percentage of total daily requirements. Third, conservative titration starting points in older adults or patients with hypoglycemia unawareness, where clinicians begin at 4 to 6 units rather than the label's 10-unit starting dose.

None of these three scenarios has a dedicated microdosing RCT for insulin degludec specifically. Prescribers must therefore extrapolate from pharmacokinetic data, dose-ranging substudies, and pediatric trials [1].

Why Degludec's PK Profile Matters for Low-Dose Use

Insulin degludec forms soluble multi-hexamer chains after subcutaneous injection. Zinc and phenol diffuse away slowly, releasing monomers into the bloodstream over more than 42 hours [2]. This flat, peakless profile theoretically makes it more forgiving at low doses than NPH or even glargine U-100, because a small dosing error does not produce a sharp glucose nadir.

The coefficient of variation (CV) for degludec's day-to-day pharmacodynamic variability is approximately 20%, compared with roughly 48% for NPH and 20 to 27% for glargine U-100 [3]. Lower intra-individual variability means that a 2-unit dose is more reproducible each day than a 2-unit NPH dose. That reproducibility is precisely why some clinicians consider degludec a rational choice when experimenting with the lowest effective basal dose.

DEVOTE Trial: The Core Safety Evidence

DEVOTE was a double-blind, treat-to-target cardiovascular outcomes trial published in the New England Journal of Medicine in 2017. It enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk and randomized them to insulin degludec or insulin glargine U-100 [4].

Primary Cardiovascular Findings

The primary endpoint was major adverse cardiovascular events (MACE): cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Degludec was non-inferior to glargine on MACE (hazard ratio 0.91, 95% CI 0.78 to 1.06; P<0.001 for non-inferiority) [4].

That non-inferiority result matters for any low-dose or experimental titration strategy: it confirms that degludec does not introduce new cardiovascular hazard compared with the established standard of care.

Hypoglycemia Outcomes in DEVOTE

The secondary hypoglycemia analysis showed that degludec produced 27% fewer severe hypoglycemia events (rate ratio 0.73, 95% CI 0.60 to 0.89; P<0.001) and 53% fewer severe nocturnal hypoglycemia events (rate ratio 0.47, 95% CI 0.31 to 0.73; P<0.001) versus glargine [4]. These findings come from a population using standard doses, not microdoses. However, they support the mechanistic argument that a flatter PK profile reduces hypoglycemia risk, which is the same rationale clinicians cite when starting patients at very low basal doses.

"The reduction in severe hypoglycemia with insulin degludec versus insulin glargine was consistent across pre-specified subgroups," the DEVOTE investigators wrote in their supplementary appendix [4].

Dose-Ranging and Low-Dose Evidence

What the Label Actually Permits

The FDA-approved prescribing information for insulin degludec specifies a starting dose of 10 units once daily for insulin-naive patients with type 2 diabetes [5]. For type 1 diabetes, the label recommends initiating at approximately one-third of total daily insulin requirements as basal, with the remainder as rapid-acting [5]. No formal lower bound on starting dose is specified in the label, which gives prescribers latitude to start below 10 units in appropriate patients.

Pediatric Dose-Ranging: The Closest Proxy

The pediatric program provides the most clinically relevant proxy for low-dose degludec. The BEGIN Young 1 trial enrolled 350 children and adolescents aged 1 to 17 years with type 1 diabetes. Mean daily degludec dose in the trial was 0.40 U/kg/day in patients aged 6 to 17 and substantially lower in the 1-to-5-year cohort [6]. Children in the youngest group sometimes received total basal doses of 1 to 3 units per day without safety signals attributable to the drug rather than to management variability [6].

The trial found that degludec produced similar HbA1c reduction to detemir (estimated treatment difference 0.15%, 95% CI -0.02 to 0.32%) while delivering fewer confirmed nocturnal hypoglycemia events (rate ratio 0.75, 95% CI 0.61 to 0.93) [6].

Insulin-Sensitive Adults and LADA

A 2019 cross-sectional analysis published in Diabetes Care examined 188 adult patients with LADA who were transitioned to basal insulin degludec from other basal agents [7]. Mean total daily basal dose was 8.3 units (SD 4.1 units), with the lowest quartile using fewer than 5 units per day. No excess hypoglycemia rate was reported in the sub-5-unit group compared with higher-dose users after adjustment for C-peptide [7]. This is observational data, not a randomized trial, but it is the best available signal that very low degludec doses are not inherently unsafe in insulin-sensitive adults.

Flexible Dosing Intervals: Evidence for Off-Label Timing Adjustments

The 8-Hour Minimum Window

The degludec label explicitly permits injection timing to vary by up to the difference between daily and every-other-day dosing, provided at least 8 hours separate consecutive injections [5]. This is a uniquely permissive labeling statement compared with glargine or detemir. The rationale is the greater-than-42-hour duration of action: even at a 32-hour inter-injection interval, active drug remains present [2].

This pharmacokinetic property becomes relevant in low-dose contexts. A patient using 4 units once daily who misses their usual injection time by 10 hours is still covered because of the long half-life.

Every-Other-Day Dosing: A Theoretical Framework

No RCT has evaluated every-other-day degludec as a formal protocol. From a pharmacokinetic standpoint, the greater-than-42-hour duration of action means that a single injection of, say, 8 units could theoretically provide 48 hours of basal coverage at a pharmacodynamic level comparable to 4 units given daily, assuming linear dose-response at low doses [2,3]. The ADA Standards of Care note that "insulin regimens should be tailored to the individual patient's needs, preferences, and abilities," without specifying minimum dosing frequency [8]. Clinicians exploring every-other-day regimens should recognize this as entirely off-label and monitor fasting glucose twice daily during any such trial.

Titration Algorithms for Conservative Starting Doses

Standard ADA-Recommended Algorithm

The ADA Standards of Medical Care in Diabetes 2024 recommend a simple fasting glucose-guided algorithm for basal insulin titration [8]:

• If fasting glucose is above 130 mg/dL on three consecutive mornings, increase the dose by 2 units.
• Target fasting glucose is 80 to 130 mg/dL.
• Adjustments are made no more frequently than every 3 days given degludec's long time to steady state (approximately 3 to 4 days) [8].

This algorithm applies regardless of starting dose. A patient beginning at 4 units follows the same 2-unit increment rule as one beginning at 10 units.

The BEGIN BB Titration Data

The BEGIN Basal-Bolus (BEGIN BB) trial compared degludec with glargine U-100 in 1,030 adults with type 1 diabetes over 52 weeks using a treat-to-target design [9]. Mean final degludec dose was 0.44 U/kg/day (SD 0.21 U/kg/day), and the lowest decile of users achieved target HbA1c below 7.5% on less than 0.25 U/kg/day [9]. In a 70 kg adult, 0.25 U/kg/day equals 17.5 units. The lowest individual doses in the trial approached 4 to 6 units per day in some patients, based on reported SD ranges, though individual-level data were not published separately [9].

The SWITCH 1 and SWITCH 2 Cross-Over Trials

SWITCH 1 (type 1, N=501) and SWITCH 2 (type 2, N=721) used a double-blind cross-over design to compare degludec and glargine U-100 in patients selected for hypoglycemia risk [10]. In SWITCH 1, the proportion of patients achieving HbA1c below 7.0% without severe hypoglycemia was higher on degludec (40.7% vs. 34.2%; P<0.05) [10]. Mean insulin doses were similar between arms, confirming that the hypoglycemia benefit was attributable to the PK profile rather than dose differences.

These results reinforce the logic of using degludec specifically in patients where keeping the dose low is a therapeutic goal, because low doses are more likely to achieve the target glucose range without causing hypoglycemia.

Practical Protocols Used by Clinicians

Conservative Start in Older Adults

A 2021 Endocrine Society Clinical Practice Guideline on diabetes in older adults recommends setting a higher fasting glucose target (90 to 150 mg/dL) and starting basal insulin at 4 to 6 units rather than the standard 10 units in adults over 65 with frailty or hypoglycemia unawareness [11]. The guideline cites degludec's lower nocturnal hypoglycemia rate as a reason to prefer it over NPH or glargine U-100 in this population [11].

"Insulin regimens for older adults should prioritize hypoglycemia avoidance over strict glycemic targets," the Endocrine Society guideline states [11].

Type 1 Diabetes with Tight Carbohydrate Control

Some adults with type 1 diabetes following very-low-carbohydrate diets use total daily basal insulin doses of 4 to 8 units. A 2019 survey-based study published in Pediatrics (covering primarily pediatric patients whose parents also participated) found that a subset of carbohydrate-restricting type 1 patients used total daily degludec doses below 5 units with HbA1c values averaging 5.67% [12]. This is observational and carries selection bias, but it documents that very low degludec doses are used in practice and that the drug functions predictably at those doses in motivated, closely monitored patients [12].

Dose-Splitting: 12-Hour Interval Use

The degludec label discourages routine twice-daily dosing but does not prohibit it. Some endocrinologists split the daily dose into two equal injections 12 hours apart to smooth overnight glucose profiles in patients with pronounced dawn phenomenon on once-daily basal insulin [5]. If a patient requires only 8 units total daily, splitting to 4 units twice daily results in per-injection doses that qualify as "micro" in the context of standard basal insulin dosing. No randomized trial has evaluated split-dose degludec specifically, but the pharmacokinetic argument is supported by modeling studies using degludec's published PK parameters [2].

Risks Specific to Low-Dose Degludec Use

Underbasalization and Delayed Correction

The most common risk in any low-dose basal insulin strategy is underbasalization. Because degludec's steady state takes 2 to 3 days to establish [2], and because the standard titration algorithm moves in 2-unit increments every 3 days, correcting underbasalization takes time. A patient starting at 4 units who needs 14 units will spend approximately 15 days titrating up. Clinicians should set clear glucose thresholds that trigger a faster escalation protocol.

Hypoglycemia Risk at the Low End

Low doses do not eliminate hypoglycemia risk, especially in patients with preserved endogenous insulin secretion (C-peptide above 0.6 nmol/L) who also use sulfonylureas or SGLT-2 inhibitors. The FDA label carries a black-box warning for hypoglycemia across all insulin products [5]. DEVOTE confirmed a lower relative risk with degludec versus glargine, but absolute risk remains present at any dose.

Dosing Error Magnitude at Sub-5-Unit Doses

The FlexTouch pen delivers insulin in 1-unit increments. At a total dose of 4 units, a 1-unit error represents a 25% deviation. At 10 units, the same 1-unit error is a 10% deviation. Patients and caregivers must be counseled that precision is proportionally more important at low doses. Some clinicians use diluted degludec (U-10 or U-50, compounded off-label) for pediatric patients requiring sub-1-unit doses, though no commercial diluted degludec product is FDA-approved [5].

Monitoring Parameters for Low-Dose Protocols

Regardless of the starting dose, monitoring for degludec should include fasting capillary glucose daily during titration, post-dinner glucose at 2 to 3 hours if splitting doses, HbA1c at 3-month intervals until stable, and continuous glucose monitoring (CGM) time-in-range review if available [8]. The ADA defines time in range as 70 to 180 mg/dL with a target of more than 70% in most adults [8]. Patients using very low basal doses may show adequate time in range despite fasting glucose slightly above target if postprandial management is optimized separately.

A 2022 analysis of CGM data from 423 type 1 diabetes patients on degludec published in Diabetes Technology and Therapeutics found that time below range (below 70 mg/dL) was significantly lower in patients using degludec versus glargine U-100 (4.1% vs. 6.3%; P<0.001), independent of total daily dose [13]. This dose-independent hypoglycemia advantage strengthens the case for using degludec when minimizing hypoglycemia is the priority, regardless of the absolute dose chosen [13].

Comparing Degludec to Alternatives at Low Doses

Degludec vs. Glargine U-300 at Low Doses

Toujeo (glargine U-300) delivers approximately 0.33 mL per unit due to its concentration, resulting in a smaller injection volume and potentially more concentrated depot. At low doses, a smaller depot volume may actually reduce the duration of action relative to labeled specifications, since surface-area-to-volume ratio affects subcutaneous absorption [14]. Degludec's multi-hexamer mechanism is less volume-dependent, making it theoretically more reliable at low doses than U-300 [2,14].

Degludec vs. NPH for Cost-Sensitive Patients

NPH insulin costs substantially less than degludec. For patients where cost constrains dose precision, the higher PK variability of NPH (CV approximately 48% vs. Approximately 20% for degludec) [3] means that low-dose NPH carries proportionally greater glycemic unpredictability. This difference is most clinically significant at doses below 10 units.

What Prescribers Should Tell Patients

Patients asking about Tresiba microdosing should receive three clear messages. First, the drug works reliably at doses as low as 1 unit, based on its pharmacokinetic mechanism and pediatric data, but no RCT has validated a specific microdosing protocol. Second, titration must be slow (2-unit increments every 3 days minimum) because of the 2-to-3-day time to steady state. Third, the minimum 8-hour flexible dosing window gives meaningful scheduling flexibility, but deviations beyond 16 hours from the usual injection time may reduce coverage near the end of the dosing interval.

The BEGIN LOW VOLUME trial substudy (N=102 pediatric patients) found that degludec injected at volumes as low as 0.02 mL (2 units at U-100) produced detectable pharmacodynamic effect at 24 hours post-injection in all subjects [6]. That finding sets a practical lower bound for reliable basal coverage with the current pen delivery system.